Table 5.

Hepta-, polycyclic and dimeric proline-based DKP.

Entry	Structure	Name	Cell Line	IC50 [μM]	Reference
Heptacyclic
1	Speramide A (69)		PC3	>40	[135]
			DU145	>40	[135]
			LNCaP	>40	[135]
2	Stephacidin A (70)		PC3	2.1	[136]
			LNCaP	1	[136]
			A2780	4	[136]
			A2780/DDP	6.8	[136]
			A2780/Tax	3.6	[136]
			HCT116	2.1	[136]
			HCT116/mdr+	6.7	[136]
			HCT116/topo	13.1	[136]
			MCF-7	4.2	[136]
			SKBR3	2.15	[136]
			LX-1	4.22	[136]
3	71	Drimentine I	HeLa	16.73	[137]
			A549	n.a.	[137]
4	72	Gartryprostatin A	MV4-11	7.2	[138]
			K562	> 10, 19.7 1	[138]
			HL-60	> 10, 20.6 1	[138]
			A549	> 10, 15.2 1	[138]
5	73	Gartryprostatin B	MV4-11	10	[138]
			K562	> 10, 18.5 1	[138]
			HL-60	> 10, 23.2 1	[138]
			A549	> 10, 18.2 1	[138]
6	74	(+)-Avrainvillamide	HeLa	1.1 2	[87]
			T-47D	0.33 3	[139]
			LNCaP	0.423	[139]
			NB4	1.1	[140]
			HL-60	0.643	[140]
			MV4-11	0.116	[140]
			OCI-AML3	0.112	[140]
			Molm-13	0.078	[140]
7	75	(−)-Avrainvillamide	T-47D	0.91 3	[139]
			LNCaP	1.4 3	[139]
Polycyclic
8	76	Waikikiamide A	HT1080	0.519	[141]
			PC3	1.855	[141]
			Jurkat	0.62	[141]
			A2780S	0.78	[141]
Dimeric
9	Waikikiamide B (77)		HT1080	1.135	[141]
			PC3	1.805	[141]
			Jurkat	1.79	[141]
			A2780S	1.127	[141]
10	Stephacidin B (78)		PC3	0.37	[136]
			LNCaP	0.06	[136]
			A2780	0.33	[136]
			A2780/DDP	0.43	[136]
			A2780/Tax	0.26	[136]
			HCT116	0.46	[136]
			HCT116/mdr+	0.46	[136]
			HCT116/topo	0.42	[136]
			MCF-7	0.27	[136]
			SKBR3	0.32	[136]
			LX-1	0.38	[136]
11	Naseseazine A (79)		AGS	n.a.	[142]
			SH-SY5Y	n.a.	[142]
			TF-1	n.a.	[142]
			HT-29	n.a.	[142]
12	Naseseazine B (80)		AGS	n.a.	[142]
			SH-SY5Y	n.a.	[142]
			TF-1	n.a.	[142]
			HT-29	n.a.	[142]
13	Asperflocin (81)		HT-29	>20	[143]
			A375	10.29 ± 2.37	[143]
			MCF-7	>20	[143]
			HepG2	>20	[143]
14	WIN 64821 (82)		HT-29	>20	[143]
			A375	>20	[143]
			MCF-7	>20	[143]
			HepG2	>20	[143]

¹ Inhibition rate at 10 μM; ² IC₉₀ [μg/mL]; ³ GI₅₀ [μM]; n.a.—not active.